Placebo News and Research

RSS

Study investigates use of stem cells to treat lower-limb peripheral artery disease

Research led by vascular surgeons at Dartmouth-Hitchcock may offer new hope to sufferers of peripheral artery disease, the cause of nearly 60,000 lower-limb amputations annually, through the use of a patient's own stem cells.

3 May 2012

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

After nearly 13 years of study and intense debate, a pair of new papers from the Perelman School of Medicine, at the University of Pennsylvania have confirmed exactly how a once-popular class of anti-inflammatory drugs leads to cardiovascular risk for people taking it.

3 May 2012

Fish oil may improve outcomes for kidney patients undergoing hemodialysis

Over the past decade, there has been a steady stream of information promoting the health benefits of fish oil capsules. According to Dr. Louise Moist, a Scientist at Lawson Health Research Institute, fish oil may also improve outcomes for kidney patients undergoing hemodialysis.

2 May 2012

JLGTD to publish results from Cutaneous Lysate study on vulvodynia

The results from Dr. Gilbert G. Donders' MD, PhD study testing Cutaneous Lysate in women suffering from vulvar pain has been accepted for publication in the Journal of Lower Genital Tract Disease.

2 May 2012

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Ultragenyx Pharmaceutical Inc., a biotechnology company focused on developing treatments for rare and ultra-rare genetic disorders, today announced results from a first-in-human, multi-center, Phase 1 study of UX001 in patients with hereditary inclusion body myopathy (HIBM) showing that UX001 was well-tolerated with an expected extended release profile on absorption after oral administration

2 May 2012

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Inovio Pharmaceuticals, Inc. announced today that the United States Patent and Trademark Office granted U.S. Patent No. 8,168,769, covering Inovio's SynCon vaccine for cervical dysplasias and cancers caused by human papillomavirus (HPV).

2 May 2012

Array BioPharma third quarter revenue increases to $19.1M

Array BioPharma Inc. today reported financial results for the third quarter of fiscal 2012.

2 May 2012

Gilead commences GS-1101 Phase 3 trial in CLL

Gilead Sciences, Inc. today announced that the first patient has been dosed in a Phase 3 clinical trial evaluating the efficacy and safety of GS-1101.

2 May 2012

ACE inhibitors or ARBs could treat and prevent PTSD

Traumatized people who take a class of common blood pressure medications tend to have less severe post-traumatic stress symptoms, researchers have found.

2 May 2012

FDA approves Levaquin for plague

The U.S. Food and Drug Administration today approved Levaquin (levofloxacin) to treat patients with plague, a rare and potentially deadly bacterial infection. The agency also approved the drug to reduce the risk of getting plague after exposure to Yersinia pestis, the bacterium that causes the disease.

30 Apr 2012

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Syndax Pharmaceuticals, Inc., a late-stage oncology company focused on the clinical development of epigenetic therapies in solid tumors, announced that previously reported results from ENCORE 401, a randomized, placebo controlled Phase 2 study of erlotinib with or without entinostat in advanced non-small cell lung cancer patients were published in the Journal of Clinical Oncology (JCO).

30 Apr 2012

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

Zalicus Inc., a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain and immuno-inflammatory diseases, today announced it has completed enrollment with 292 patients enrolled in the SYNERGY trial, a Phase 2b clinical trial designed to evaluate the safety and efficacy of Synavive, a low-dose glucocorticoid with the potential for amplified immuno-inflammatory benefits, in patients with rheumatoid arthritis (RA).

30 Apr 2012

VIVUS receives FDA approval for Stendra to treat erectile dysfunction

The U.S. Food and Drug Administration today approved Stendra (avanafil), a new drug to treat erectile dysfunction.

30 Apr 2012

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

VIVUS, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved STENDRA (avanafil) tablets for the treatment of erectile dysfunction (ED), marking the first new prescription agent approved in nearly a decade for the condition that afflicts as many as 30 million men in the U.S.

30 Apr 2012

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

Novartis Pharmaceuticals Corporation announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with kidney tumors known as renal angiomyolipomas and tuberous sclerosis complex (TSC), who do not require immediate surgery.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

The U.S. Food and Drug Administration approved Afinitor (everolimus), the first drug approved specifically to treat non-cancerous kidney tumors (renal angiomyolipomas) not requiring immediate surgery in patients with tuberous sclerosis complex.

27 Apr 2012

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced the initiation of a Phase 2 clinical trial evaluating the preliminary efficacy and safety of INNO-206 in patients with advanced pancreatic ductual adenocarcinomas (PDA) who have progressed after receiving two prior therapies.

26 Apr 2012

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

John W. Tsuang, M.D., principal investigator at the Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center (LA BioMed), in conjunction with Steven J. Shoptaw, Ph.D., from the UCLA Department of Family Medicine, is spearheading a Phase I clinical safety trial that for the first time examines the effects of Ibudilast when administered with metamphetamine (MA), an addictive stimulant that is closely related to amphetamine.

26 Apr 2012

Placebo News and Research

Study investigates use of stem cells to treat lower-limb peripheral artery disease

Study confirms that COX-2 inhibitors predispose people to cardiovascular disease

Fish oil may improve outcomes for kidney patients undergoing hemodialysis

JLGTD to publish results from Cutaneous Lysate study on vulvodynia

Ultragenyx reports results from UX001 Phase 1 study on HIBM

Inovio's SynCon vaccine for cervical dysplasias and cancers granted U.S. patent

Array BioPharma third quarter revenue increases to $19.1M

Gilead commences GS-1101 Phase 3 trial in CLL

ACE inhibitors or ARBs could treat and prevent PTSD

FDA approves Levaquin for plague

JCO publishes Syndax erlotinib-entinostat Phase 2 study for advanced non-small cell lung cancer

Enrollment complete in Zalicus Synavive Phase 2b clinical trial for rheumatoid arthritis

VIVUS receives FDA approval for Stendra to treat erectile dysfunction

FDA approves VIVUS’ STENDRA for treatment of erectile dysfunction

FDA approves Novartis’ Afinitor for treatment of renal angiomyolipomas and TSC

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Novartis receives FDA approval for Afinitor to treat renal angiomyolipomas caused by TSC

CytRx commences INNO-206 Phase 2 clinical trial for pancreatic cancer

First-ever study to evaluate effects of interaction between metamphetamines and Ibudilast

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News